A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors

计划入组 202 人 · 首次发布于 2024 年 10 月 24 日

Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure in Subjects at Increased Immunological Risk

计划入组 368 人 · 首次发布于 2007 年 3 月 14 日

Study to Assess LX201 for Prevention of Corneal Allograft Rejection or Graft Failure in Subjects Who Have Experienced One or More Rejection Episodes Following Penetrating Keratoplasty

计划入组 122 人 · 首次发布于 2007 年 3 月 15 日

AXV201

OAV201

NV201

Laverock Therapeutics Raises £20M in Expanded Seed Funding, Reports Positive Data for Cancer Cell Therapy Programs

Formation Bio Doses First Participant in Phase 1 Trial of CNS-Penetrant TYK2 Inhibitor BLKR201

China's Personalized mRNA Cancer Therapy Sector Accelerates as LK101 Advances Toward Clinical Validation